[1]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147-149.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Journal of Medical Information,2018,31(22):147-149.[doi:10.3969/j.issn.1006-1959.2018.22.043]
点击复制

恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年22期
页码:
147-149
栏目:
药物与临床
出版日期:
2018-11-15

文章信息/Info

Title:
Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection
文章编号:
1006-1959（2018）22-0147-03
作者:
叶向荣
（九江学院附属医院消化内科，江西 九江 332000）
Author(s):
YE Xiang-rong
(Department of Gastroenterology,Affiliated Hospital of Jiujiang University, Jiujiang 332000, Jiangxi,China)
关键词:
恩替卡韦; 慢性乙型肝炎; 病毒感染
Keywords:
Entecavir; Chronic hepatitis B; Viral infection
分类号:
R512.62
DOI:
10.3969/j.issn.1006-1959.2018.22.043
文献标志码:
A
摘要:
目的 观察与评价恩替卡韦治疗慢性乙型肝炎病毒感染患者临床价值。方法 选取2015年10月~2018年7月在我院接受慢性乙型肝炎治疗的患者96例，随机分为对照组与研究组，各48例。对照组选择阿德福韦脂片治疗，研究组选择恩替卡韦治疗。对比两组患者治疗总有效率、不良反应情况，ALT、HBV-DNA水平及HBeAg转阴率指标。结果 研究组的治疗总有效率为95.83%，高于对照组的79.17%，差异有统计学意义（P＜0.05）；研究组患者腹泻、恶心及头晕的发生率均低于对照组，差异有统计学意义（P＜0.05）；治疗后，研究组患者ALT、HBV-DNA水平均高于对照组，差异有统计学意义（P＜0.05）；研究组患者HBeAg效价水平为（2.78±0.56）S/CO，低于对照组的（4.23±1.21）S/CO，差异有统计学意义（P＜0.05）。结论 慢性乙型肝炎病毒感染患者接受恩替卡韦治疗的效果更佳，可有效提升ALT、HBV-DNA水平，降低HBeAg效价水平，不良反应发生率低。
Abstract:
Objective To observe and evaluate the clinical value of entecavir in the treatment of chronic hepatitis B virus infection. Methods 96 patients with chronic hepatitis B treated in our hospital from October 2015 to July 2018 were randomly divided into control group and study group, 48 cases in each group. The control group was treated with adefovir dipivoxil tablet and the study group was treated with entecavir. The total effective rate, adverse reactions, ALT, HBV-DNA levels and HBeAg negative conversion rate were compared between the two groups. Results The total effective rate of the study group was 95.83%, higher than 79.17% of the control group, with significant difference (P<0.05); The incidence of diarrhea, nausea and dizziness in the study group was lower than that in the control group, and the difference was statistically significant (P<0.05). After treatment, the ALT and HBV-DNA levels in the study group were higher than those in the control group,the difference was statistically significant (P<0.05). The HBeAg titer level of the study group was (2.78±0.56) S/CO, which was lower than that of the control group (4.23±1.21) S/CO,the difference was statistically significant (P<0.05). Conclusion Patients with chronic hepatitis B virus infection are more effective in receiving entecavir, which can effectively improve ALT and HBV-DNA levels, lower HBeAg titer, and have a lower incidence of adverse reactions.

参考文献/References:


[1]王栋平.茵芪三黄解毒汤联合恩替卡韦治疗慢性乙型肝炎的临床研究[D].北京中医药大学,2018.
[2]赵琴.恩替卡韦治疗慢性乙型肝炎的病毒载量、细胞因子及肝纤维化指标动态变化[J].中国临床医生杂志,2018,46(3):288-290.
[3]宁晓艳,周旸,黄鑫,等.恩替卡韦联合α-干扰素治疗慢性乙型肝炎临床研究[J].中国现代药物应用,2017,11(23):106-108.
[4]尹盛才.恩替卡韦治疗慢性乙型肝炎病毒感染患者的临床效果[J].医疗装备,2017,30(21):92-93.
[5]曹孟,李玮等.恩替卡韦治疗拉米夫定耐药性慢性乙型肝炎的临床研究[J].临床误诊误治,2017,30(9):81-84.

相似文献/References:

[1]唐平阳.恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的 临床疗效分析[J].医学信息,2018,31(10):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
　TANG Ping-yang.Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(22):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
[2]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和 生活质量的影响研究[J].医学信息,2018,31(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
　LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2018,31(22):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[3]姜海燕.恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化对患者肝功能及血清HA、Ⅳ-C、PC-Ⅲ水平的影响[J].医学信息,2022,35(09):144.[doi:10.3969/j.issn.1006-1959.2022.09.036]
　JIANG Hai-yan.Effect of Entecavir Combined with Compound Glycyrrhizin on Liver Function and Serum Levels of HA, Ⅳ-C and PC-Ⅲ in Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2022,35(22):144.[doi:10.3969/j.issn.1006-1959.2022.09.036]
[4]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
　LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Journal of Medical Information,2018,31(22):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[5]陈 欢,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者 肝功能及血脂水平分析[J].医学信息,2019,32(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
　CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute, Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(22):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
[6]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义[J].医学信息,2018,31(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
　WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Journal of Medical Information,2018,31(22):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[7]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
　WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Journal of Medical Information,2019,32(22):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[8]马 琳,田瑞民.乙型病毒性肝炎相关晚期肝病的抗病毒治疗效果观察[J].医学信息,2019,32(07):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
　MA Lin,TIAN Rui-min.Observation on the Effect of Antiviral Therapy For Advanced Hepatopathy Associated with Viral Hepatitis B[J].Journal of Medical Information,2019,32(22):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
[9]傅 蕊,李士欣,周国强,等.床旁超声预测慢性乙型肝炎患者胃镜检查围麻醉期误吸风险的临床价值[J].医学信息,2019,32(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
　FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2019,32(22):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[10]张媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的临床特点[J].医学信息,2019,32(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
　ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2019,32(22):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[11]张 瑜,路青华,曹海芳,等.聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响[J].医学信息,2021,34(17):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]
　ZHANG Yu,LU Qing-hua,CAO Hai-fang,et al.Effect of Polyethylene Glycol Interferon,PEG-IFN Combined with Entecavir on Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2021,34(22):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]

更新日期/Last Update: 2018-12-03